Serum substitute as well as preparation method and application thereof

CN119032164APending Publication Date: 2024-11-26SHANGHAI WOLWO STEM CELL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031996.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-06
Filing Date
2023-04-04
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the existing technology, animal serum is expensive and the quality is uncontrollable, and known serum substitutes are widely available and lack safety and stability, making it difficult to meet the needs of stem cell culture.

Method used

Using a controllable source of bovine blood, through platelet lysis and strict quality control, a serum substitute that meets the standards of the Pharmacopoeia of the People's Republic of China is prepared, including platelet lysate and plasma, for the culture and differentiation of stem cells.

Benefits of technology

It provides high-quality, safe and stable serum substitutes, significantly improves the proliferation and differentiation potential of stem cells, and meets the needs of stem cell culture and induction of differentiation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000017_0000
    Figure 00000017_0000
  • Figure 00000017_0001
    Figure 00000017_0001
  • Figure 00000017_0002
    Figure 00000017_0002
Patent Text Reader

Abstract

The invention provides a serum substitute and a preparation method and application thereof, the serum substitute contains fetal cattle or newborn cattle-derived platelet lysate and plasma, and can be prepared by performing platelet lysis on fetal cattle or newborn cattle-derived platelet plasma.
Need to check novelty before this filing date? Find Prior Art

Description

Serum substitute and its preparation method and application Technical Field

[0001] The present invention relates to a serum substitute, and a preparation method and application thereof. Background Art

[0002] Stem cells are a type of multipotent cell with the ability to self-replicate. Under certain conditions, they can differentiate into a variety of functional cells. Mesenchymal stem cells are a member of the stem cell family and are found in a variety of tissues, such as hair follicles, umbilical cord, endometrium, and fat, with multidirectional differentiation potential. These stem cells possess the trilineage differentiation potential of mesenchymal stem cells, such as inducible differentiation into osteoblasts, chondrocytes, and adipocytes, as well as the potential to differentiate into other cell types. They also possess unique cytokine secretion, immunomodulatory, and anti-inflammatory properties.

[0003] Blood consists of the liquid component plasma and the blood cells suspended within it, collectively known as whole blood. After blood is isolated from the body and anticoagulated and then centrifuged, the resulting cell-free liquid is plasma. Plasma can be considered the extracellular matrix of blood, primarily transporting blood cells, substances necessary for life, and waste products. After blood is isolated from the body coagulates, the fluid released by the clot is serum. Serum is free of the fibrinogen and certain coagulation factors found in plasma. Its primary function is to provide essential nutrients, hormones, and various growth factors. Generally speaking, the main difference between plasma and serum is that plasma contains fibrinogen. Platelets are one of the major formed elements of blood and play a vital role in hemostasis. Furthermore, during platelet activation and degranulation, a large number of factors are released that participate in inflammatory responses and tissue repair.

[0004] High-efficiency stem cell culture has long been a challenge in the field, and cell culture is essential for the growth and proliferation of cells. Animal serum, a major component of stem cell culture medium, plays a crucial role in cell growth and reproduction. Among animal serums, bovine serum is the most widely used, making it a crucial raw material for pharmaceutical and biotechnology products. Bovine serum can be categorized by the period of blood collection as fetal bovine serum (FBS), newborn calf serum (NBS), calf serum (CBS), and adult bovine serum (ABS). However, animal serum is not only expensive but also suffers from uncontrollable quality, with significant stability variations between batches. Consequently, an increasing number of researchers are developing serum substitutes. For example, Patent Publication No. "CN107384856A" discloses a method for preparing platelet lysate, and Patent Publication No. "CN101486996A" discloses a non-animal-derived cell culture serum substitute. Existing serum substitutes are all derived from humans and are available in relatively low quantities. Therefore, there is an urgent need to develop serum substitutes that are widely available, have high yields, and are safe and stable.

[0005] Summary of the Invention

[0006] The present invention uses a controllable source of bovine blood to ensure its traceability and implement strict quality control standards. In addition, the serum substitute preparation process provided by the present invention can obtain a high-quality, safe, and stable serum substitute product. The serum substitute product of the present invention meets the quality control standards for newborn calf serum in the general rules of the Pharmacopoeia of the People's Republic of China (2020 edition).

[0007] In one aspect, the present invention provides a serum substitute comprising platelet lysate and plasma, wherein the platelet lysate and plasma are derived from fetal bovine or newborn calf. In some embodiments, the serum substitute comprises platelet lysate and plasma derived from fetal bovine or newborn calf. Preferably, the serum substitute is prepared using the method of the present invention for preparing a serum substitute.

[0008] In another aspect, the present invention provides a method for preparing a serum substitute, the method comprising subjecting fetal bovine or newborn calf-derived platelet plasma to platelet lysis.

[0009] In some embodiments, the method further comprises separating and removing blood cells other than platelets from fetal bovine whole blood or newborn calf whole blood to obtain the platelet plasma; and, optionally, comprising a sterilizing grade filtration step after platelet lysis.

[0010] In some embodiments, blood cells other than platelets are separated and removed by centrifugation, preferably differential centrifugation, preferably under low temperature conditions.

[0011] In some embodiments, platelet lysis is performed by freeze-thaw.

[0012] The present invention also provides the use of the serum substitute of the present invention in culturing stem cells and inducing stem cell differentiation. Examples of such stem cells include mesenchymal stem cells, such as human hair follicle mesenchymal stem cells, human umbilical cord mesenchymal stem cells, human adipose mesenchymal stem cells, and human periuterine mesenchymal stem cells. Compared to existing animal serum, the serum substitute of the present invention can significantly enhance the proliferation and differentiation potential of stem cells, such as mesenchymal stem cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] FIG1 shows the cell yield obtained by isolating and culturing primary umbilical cord mesenchymal stem cells using a culture medium containing fetal bovine serum and a culture medium containing the fetal bovine serum substitute of the present invention.

[0014] FIG2 shows the cell yield obtained by isolating and culturing primary hair follicle mesenchymal stem cells using a culture medium containing fetal bovine serum and a culture medium containing the fetal bovine serum substitute of the present invention.

[0015] FIG3 shows the adipogenic differentiation of hair follicle mesenchymal stem cells induced in a culture medium containing fetal bovine serum and a culture medium containing the fetal bovine serum substitute of the present invention. DETAILED DESCRIPTION

[0016] Unless otherwise specified, the various technical features described herein, such as content, steps, condition parameters, etc., are not limited to the various embodiments and examples specifically described herein in their combination, and any other arbitrary combination thereof also falls within the scope of the present invention.

[0017] As used herein, unless otherwise specified, numerical ranges expressed as two or more extreme values ​​are deemed to specifically disclose all real numbers between the two extreme values, and any combination thereof. Furthermore, unless otherwise specified, when multiple optional numerical ranges or values ​​are specifically described for the same parameter, these extreme values ​​and values ​​may be combined in any manner, and the resulting ranges fall within the scope of the present invention as long as they are contained within the maximum continuous range specifically described.

[0018] Herein, unless otherwise specified, the numerical value or numerical range, whether or not preceded by the word "about", covers an approximate range equivalent to the numerical value or numerical range that can be understood by technicians in the relevant field, such as the range of ±10% of the numerical value or end value, or the range of ±5%, ±3%, ±2%, ±1% or ±0.5%.

[0019] Herein, unless otherwise specified, all scientific and technical terms have the meanings generally known or acknowledged in the art, especially in the art of stem cells, mesenchymal stem cells, and culture media, such as those described in textbooks, test manuals, or prior art documents.

[0020] As used herein, open-ended expressions such as "comprising" do not exclude unspecified elements, such as other components in the case of compositions and other steps in the case of methods. Closed-ended expressions such as "consisting of" include only the specified elements, but, in the case of compositions, may include impurities in typical amounts, and in the case of methods, may include unspecified but essential steps. Open-ended expressions encompass and are deemed to specifically disclose situations limited by closed-ended expressions.

[0021] In this document, features such as steps arranged with numbers or letters such as "a", "b", ..., "I", "II", ..., "(first) (1)", "(second) (2)", etc., have no ordering meaning, only distinction or counting meaning, unless otherwise specified.

[0022] As used herein, unless otherwise specified, the conjunction "or" is synonymous with "and / or," indicating that one or more items or circumstances are included, unless the elements are incompatible. For example, as used herein, "fetal bovine or newborn calf source" means either fetal bovine or newborn calf source, including both.

[0023] The present invention provides a serum substitute containing platelet lysate and plasma derived from fetal bovine or newborn calf.

[0024] As used herein, the definition of a fetus or newborn calf is well known to those skilled in the art and is generally based on the age of the calf and whether or not it has been fed. For example, a fetus can be a bovine embryo between 5 and 8 months old in a pregnant cow, while a newborn calf can be a calf that has been born within 14 hours and has not been fed. Furthermore, a calf can be a calf under one year old, while an adult calf can be a calf over one year old.

[0025] In some embodiments, the serum replacement consists of platelet lysate and plasma, but does not exclude impurities that are typically present.

[0026] Preferably, the serum substitute is prepared by the method for preparing a serum substitute of the present invention described below, that is, the serum substitute can be prepared by platelet lysis of platelet plasma from fetal bovine or newborn calf.

[0027] To this end, the present invention provides a method for preparing a serum substitute and the serum substitute prepared thereby, wherein the method comprises subjecting fetal bovine or newborn calf-derived platelet plasma to platelet lysis.

[0028] In the present invention, "platelet plasma" refers to plasma containing platelets but not other blood cells such as red blood cells and white blood cells, and includes, for example, platelet-rich plasma and platelet concentrates. For example, platelet plasma can be prepared by separating and removing blood cells other than platelets, such as red blood cells and white blood cells, from whole blood.

[0029] In the present invention, the whole blood used to prepare platelet-rich plasma can preferably be collected from fetal bovine or newborn calf. Before collecting the bovine blood, a conventional anticoagulant can be added to the collection container to prevent the bovine blood from coagulating. Commonly used anticoagulants in the art include oxalate, heparin, citrate, ethylenediaminetetraacetic acid (EDTA), and the like. In a preferred embodiment, the anticoagulant is sodium heparin. When collecting bovine blood, it should be noted that the sampling site needs to be disinfected, and the syringe and test tube used for blood collection must be kept clean and dry.

[0030] To produce platelet plasma, one embodiment can utilize the different densities of blood cells and plasma to separate the different components using centrifugation to obtain the target component. In the present invention, when using centrifugation to produce platelet plasma, the supernatant after centrifugation is collected to obtain platelet plasma.

[0031] Commonly used centrifugation techniques include sedimentation centrifugation, differential centrifugation, density centrifugation, etc. Differential centrifugation increases the centrifugal speed by graded centrifugation or alternately performs high-speed and low-speed centrifugation, so that substances with different sedimentation coefficients are deposited in batches from the mixed solution to the bottom of the tube. In some embodiments, in order to improve the yield, multiple centrifugations can be performed, preferably differential centrifugation with a changed speed, and after one or more low-speed centrifugations, the remaining part from which the supernatant has been removed is subjected to one or more high-speed centrifugations, and the collected supernatants are combined. Preferably, differential centrifugation can be used to separate and remove blood cells other than platelets (hereinafter referred to as "other blood cells").

[0032] Preferably, to avoid sample inactivation during preparation, one preferred embodiment uses low-temperature centrifugation (e.g., low-temperature differential centrifugation) to separate and remove other blood cells. For example, the low temperature can be below 10°C, or below 5°C, such as 4°C or lower.

[0033] Centrifugal speed can be expressed in different units. Low-speed centrifugation is often expressed in revolutions per minute (rpm), while high-speed centrifugation uses "g" or "xg." "g" and "xg" both represent the acceleration due to gravity and are synonymous and interchangeable. For example, 1000g and 1000xg are synonymous. Relative centrifugal force (RCF) is the ratio of centrifugal force to gravity and is equal to the value preceding "g" or "xg." For example, a centrifugal force of 1000g or 1000xg would indicate a relative centrifugal force of 1000.

[0034] The present invention can use one or more centrifugations at the same or different centrifugation speeds to remove other blood cells. The centrifugation speed can be 400g to 2100g, such as 800g to 2000g, 400g to 1000g, or 1800g to 2100g. The centrifugation time can be 10 to 30 minutes, such as 15 to 20 minutes, 10 to 25 minutes, or 15 to 30 minutes. In some embodiments, the centrifugation to remove other blood cells comprises at least one centrifugation at 400g to 1000g for 10 to 25 minutes, preferably at a low temperature, such as 4°C.

[0035] In some embodiments, differential centrifugation is used to remove other blood cells. In some embodiments, the differential centrifugation includes at least one low-speed centrifugation and at least one high-speed centrifugation thereafter. In such embodiments, a relatively low-speed centrifugation condition is set to achieve a preliminary separation of blood cells and plasma and to dissolve the retained platelets in the plasma, thereby obtaining a platelet plasma supernatant layer retaining platelets and a sediment layer enriched with other blood cells. Any centrifugation condition that can achieve such an effect can be used as the "low-speed centrifugation" condition of the present invention. For example, the rotation speed of the low-speed centrifugation can be 400g to 1000g, and the time can be 10 to 25 minutes, preferably at a low temperature, such as 4°C. For example, the rotation speed of the centrifugation can be 400g, 600g, 800g, 1000g; the time can be 10 minutes, 15 minutes, 20 minutes, or 25 minutes. In one preferred embodiment, the low-speed centrifugation is performed at 400 g for 15 minutes at 4° C.; in another preferred embodiment, the low-speed centrifugation is performed at 800 g for 10 minutes at 4° C. If not used immediately, the supernatants obtained from each round of low-speed centrifugation can be stored separately or combined and frozen, for example, at -80° C. to -4° C.

[0036] In this embodiment, a relatively high-speed centrifugation condition is set, and the remaining fraction after the supernatant is removed after low-speed centrifugation is subjected to re-centrifugation, thereby achieving a second separation of the incompletely separated plasma and blood cells. Any centrifugation condition that can achieve this effect can be considered the "high-speed centrifugation" condition of the present invention. This can produce completely separated plasma. It is generally believed that completely separated plasma does not contain platelets.

[0037] Herein, the expression "free of" a substance includes situations in which the substance is essentially free as understood by those skilled in the art, that is, the substance is present only in a tiny amount below the detection limit, below the standard and / or does not affect the target use and target effect of the product in which the substance is contained (e.g., the serum substitute of the present invention).

[0038] For example, the speed of the high-speed centrifugation can be 1800g-2100g, and the time can be 15-30 minutes, preferably at a low temperature, such as 4°C. For example, the speed of the centrifugation can be 1800g, 1900g, 2000g, 2100g; the time can be 15 minutes, 20 minutes, 25 minutes, 30 minutes. In one preferred embodiment, the speed of the high-speed centrifugation is 2000g, the time is 20 minutes, and the temperature is 4°C; in another preferred embodiment, the speed of the high-speed centrifugation is 2100g, the time is 15 minutes, and the temperature is 4°C. If not used immediately, the supernatants obtained from each round of high-speed centrifugation can be stored separately or combined and then frozen, for example, at -80°C to -4°C.

[0039] Platelets can be lysed by repeated melting and freezing (freeze-thaw). The freeze-thaw method can completely rupture the platelets dissolved in the plasma and their contents flow out. There is no limit to the number of freeze-thaw cycles, as long as the above-mentioned complete rupture effect can be achieved. The number of freeze-thaw cycles can be counted from the first round of thawing and then freezing of the frozen sample, or from the first round of freezing and then thawing of the non-frozen sample. In one embodiment of the present invention, after the cryopreserved platelet plasma supernatant is taken out, the number of freeze-thaw cycles is 3-7, starting from the first round of thawing and then freezing, which can be, for example, 3 times, 4 times, 5 times, 6 times, 7 times, 6 times in one preferred embodiment, and 4 times in another preferred embodiment.

[0040] When freezing, ensure that the clear liquid is completely frozen. The freezing time and temperature are determined according to actual conditions. Preferably, the freezing time is not less than 8 hours. For example, the freezing time can be 8 hours, 9 hours, 10 hours, 12 hours, or 15 hours. Preferably, the freezing temperature is not higher than -20°C. For example, the freezing temperature can be -20°C, -25°C, -40°C, -45°C, -60°C, -80°C, -100°C, or -150°C. In one preferred embodiment, the freezing temperature is -80°C, and in another preferred embodiment, it is -45°C.

[0041] Preferably, during melting, the clear liquid in the bottle is ensured to form an ice-water mixture, such as ice cubes the size of a fingernail, and the temperature does not rise. In a preferred embodiment, the temperature of the melt is 0°C.

[0042] In the present invention, the purpose of repeated freezing and thawing is to lyse platelets, and the supernatant obtained by low-speed centrifugation is rich in platelets. Therefore, in a preferred embodiment, the supernatant obtained by low-speed centrifugation is repeatedly frozen and thawed and then mixed with the supernatant obtained by high-speed centrifugation before performing subsequent operations. For ease of operation, the supernatants from low-speed and high-speed centrifugation can also be mixed before performing subsequent operations. Therefore, in another preferred embodiment, the supernatants from low-speed and high-speed centrifugation are mixed before repeated freezing and thawing.

[0043] In the present invention, a sterilization-grade filtration step may also be included after repeated freezing and thawing. Sterilization-grade filtration refers to filtration that can achieve a sterilization effect, and its target effect and / or actual effect are not necessarily limited to sterilization. For example, it may also include the removal of other impurities or microorganisms such as cell debris and mycoplasma. One of the preferred embodiments uses a 0.22 μm filter membrane for filtration. In another preferred embodiment, after filtration with a 0.22 μm filter membrane, a 0.1 μm filter membrane may be used for filtration again. The 0.1 μm filter membrane further removes mycoplasma on the basis of sterilization, improves the safety of serum substitutes, and does not affect the performance of cultured stem cells (such as proliferation ability).

[0044] The present invention also provides the use of the serum replacement of the present invention in culturing stem cells. The present invention also provides the use of the serum replacement of the present invention in inducing stem cell differentiation. Stem cells may include embryonic stem cells, adult stem cells, (induced) pluripotent stem cells, etc. Pluripotent stem cells include mesenchymal stem cells, specifically, human hair follicle mesenchymal stem cells, human umbilical cord mesenchymal stem cells, human adipose mesenchymal stem cells, and human periuterine mesenchymal stem cells. Adult stem cells may be adipose stem cells, periuterine stem cells, hair follicle stem cells, or umbilical cord stem cells. It should be noted that the term "stem cells" in the present invention does not include cells isolated or obtained from human embryos that are more than 14 days post-fertilization or have undergone in vivo development. In some embodiments, the induced stem cell differentiation may be, for example, inducing adipogenic differentiation of stem cells or inducing chondrogenic differentiation of stem cells. Serum replacements have shown good effects in inducing adipogenic differentiation or chondrogenic differentiation of stem cells. In some embodiments, the content (volume ratio) of the serum replacement in the culture medium is 5%-15%. Preferably, the content (volume ratio) of the serum replacement in the culture medium is 10%.

[0045] In a preferred embodiment, the stem cells are mesenchymal stem cells, such as human hair follicle mesenchymal stem cells, human umbilical cord mesenchymal stem cells, human adipose mesenchymal stem cells, and human periuterine mesenchymal stem cells.

[0046] Example

[0047] The present invention will be described in further detail below in conjunction with examples. However, it should be understood that these examples are only for illustrative purposes and are not intended to limit the scope of the present invention.

[0048] In this article and the accompanying drawings, "blood substitute" is the abbreviation for serum substitute.

[0049] Example 1 Preparation of serum substitute

[0050] In this example, fetal bovine serum substitute, neonatal bovine blood, calf blood, and adult bovine blood were used to prepare fetal bovine serum substitute, neonatal bovine serum substitute, calf serum substitute, and adult bovine serum substitute, respectively. Fetal bovine blood was collected by cardiac puncture from an 8-month-old cow; neonatal bovine blood was collected from unfed calves less than 14 hours old; calf blood was collected from 6-month-old calves; and adult bovine blood was collected from 18-month-old cows. The source of bovine blood is traceable and subject to strict quality control standards.

[0051] Collection and transportation of cattle blood

[0052] Before collecting bovine blood, add 100 mg of sodium heparin to a 500 mL serum bottle to achieve a final concentration of 200 mg / L. During the collection process, slowly shake the serum bottle to ensure that the bovine blood and sodium heparin are evenly mixed. After collection, transport the bovine blood at 4°C to the serum substitute preparation laboratory.

[0053] Preparation of serum replacement

[0054] The collected bovine blood was placed in a biosafety cabinet for packaging; the first round of low-speed centrifugation: centrifuged at 400g for 15 minutes at 4°C, and the centrifuge tube was slowly removed from the centrifuge. At this time, it was divided into an upper supernatant and a lower precipitate. The lower precipitate consisted of a white blood cell layer close to the upper layer and a red blood cell layer located at the lower layer. The upper supernatant was collected into a 250mL serum bottle, marked as A1, and frozen at -80°C; the second round of high-speed centrifugation: the lower precipitate with the upper supernatant removed was centrifuged at 2000g for 20 minutes at 4°C, the upper supernatant was carefully aspirated and placed in a 500mL serum bottle, marked as A2, and frozen at -20°C.

[0055] A1 was removed and equilibrated at room temperature for 10 minutes. It was then placed in a 37°C constant-temperature water bath, with the water in the water bath covering two-thirds of the bottle. The bottle was shaken at 80-100 rpm to thaw, and the temperature was observed every 10 minutes. When an ice-water mixture (0°C) was formed in the bottle, the bottle was immediately removed to complete thawing. A1 was again frozen in a -80°C ultra-low temperature freezer for at least 8 hours until it was completely frozen. This was recorded as one freeze-thaw cycle. This freeze-thaw cycle (i.e., thawing and freezing) was repeated six times.

[0056] After 6 freeze-thaw cycles, A1 and A2 were thawed separately in a 37°C constant temperature water bath, and then A1 and A2 were mixed evenly in a biosafety cabinet; finally, after filtering through a 0.22μm filter membrane, the serum substitute (abbreviated as "blood substitute") was prepared; it was divided into new serum bottles and frozen at a temperature below -15°C for later use.

[0057] Example 2 Cultivation of human hair follicle mesenchymal stem cells using serum substitutes from different sources

[0058] Obtaining primary human hair follicle mesenchymal stem cells

[0059] Complete human hair follicle tissue was obtained and placed in a 10 cm culture dish containing 10 mL of culture medium containing bovine serum. The culture medium containing bovine serum was DMEM / F12 medium (purchased from Shanghai Yuanpei Biotechnology Co., Ltd.) supplemented with 1% (v / v) penicillin / streptomycin (purchased from Biyuntian Biotechnology Research Institute) + 10% fetal bovine serum, newborn bovine serum, calf serum, or adult bovine serum. Among them, fetal bovine serum, newborn bovine serum, calf serum, and adult bovine serum were prepared by the method described in Example 1. Using a microscope, the human hair follicle tissue was carefully placed at the bottom of a 1.5 mL EP tube. Using a pipette, the culture medium carried by the human hair follicle tissue was removed as much as possible, and 8 μL of enzymatic solution was added to each hair follicle. The EP tube containing the enzymatic cell suspension was placed in a 37°C constant temperature metal bath for enzymatic hydrolysis for 3 hours, and the speed was set to 600 rpm (times / minute).

[0060] The enzymatic solution used was prepared by mixing the following components: 0.05 mL 20 mg / mL collagenase IV (Sigma-Aldrich), 0.05 mL 40 mg / mL Dispase II (Sigma-Aldrich), 0.01 mL 500 mM CaCl2 (Sigma-Aldrich), and 0.89 mL HBSS (balanced salt solution, Shanghai Yuanpei Biotechnology Co., Ltd.).

[0061] After enzymatic hydrolysis is complete, the outer root sheath of the hair follicles will be completely hydrolyzed under a microscope, while the hair shaft will not be completely hydrolyzed. Use a 20-200μL pipette to gently pipette up and down the EP tube 20 times to thoroughly mix the hydrolyzate. Let it sit for 1 minute until the undigested hair shafts sink to the bottom of the EP tube. Aspirate the upper layer of hydrolyzed suspension, which is the primary (P0) mesenchymal stem cells. Add an equal amount of AO / PI reagent and mix thoroughly. Count the cells using a Countstar fluorescence counter. For detailed instructions on using an automated cell counter, see the "Countstar Rigel S2 Automated Cell Counter Standard Operating Procedure" (WWSC-0024-CC).

[0062] Obtaining the first generation of human hair follicle mesenchymal stem cells

[0063] Pre-pipette 2 mL of DMEM / F12 medium containing 10% fetal bovine serum, newborn bovine serum, calf serum, or adult bovine serum plus 1% penicillin / streptomycin, as described above, at the bottom of each centrifuge tube. Place a cell strainer over the wells of a six-well plate. Aspirate 40 μL of the enzymatically digested cell suspension, corresponding to five hair follicles per well, through a 100 μm cell strainer. Then, use the original pipette tip to pipette the culture medium containing the various bovine serum substitutes prepared in the above centrifuge tubes through the strainer. Repeat three times. Use a 20-200 μL pipette to rinse the EP tubes with 200 μL of the culture medium containing the various bovine serum substitutes prepared in the above centrifuge tubes, then pass through the strainer. Repeat three times. Finally, pass the remaining culture medium containing the various bovine serum substitutes prepared in the above centrifuge tubes through the strainer. Incubate the six-well plate in a 37°C, 5% CO₂ incubator. After 5 days of static culture, observe and photograph the cells and change the medium. Change the medium on days 5 and 7.

[0064] After 10-12 days of culture, when the cell density in the six-well plate reaches 80% or higher, discard the culture medium. Add 0.5 mL of TrypLE to the six-well plate and incubate for 3 minutes at room temperature. Use a pipette to add 0.5 mL of DMEM / F12 medium containing 10% fetal bovine serum, newborn bovine serum, calf serum, or adult bovine serum plus 1% penicillin / streptomycin, as described above, to each culture flask to terminate digestion. After inoculation, first-generation (P1) human hair follicle mesenchymal stem cells were obtained.

[0065] Add equal amounts of AO / PI reagent and mix well. Count the cells using a Countstar fluorescence counter. For details on the use of the automatic cell counter, see "Countstar Rigel S2 Automatic Cell Counter Standard Operating Procedure" WWSC-0024-CC. The expansion factor = the number of cells harvested in the passage / the number of cells inoculated. In this example, the cell count was strictly 5000 cells / cm 2 The area of ​​a six-well plate is 10 cm 2 , that is, a six-well plate is inoculated with 0.5×10 5 cells, the expansion factor calculation formula is "expansion factor = number of cells harvested each time / (0.5×10 5 )”.

[0066] According to the above method, hair follicle tissues from two different donors were obtained. The cell yields and expansion times of the P0 and P1 generations are shown in Table 1.

[0067] Table 1 Evaluation of hair follicle cell growth by fetal bovine blood, newborn bovine blood, calf blood or adult bovine blood

[0068] The above shows that the use of fetal bovine blood and newborn bovine blood in culture medium can significantly enhance the proliferation capacity of primary and passaged mesenchymal stem cells, and fetal bovine blood is slightly better than newborn bovine blood.

[0069] Example 3 Preparation of serum substitute

[0070] The bovine blood in this embodiment is fetal bovine blood, which is obtained by puncturing the heart of a fetus in an 8-month pregnant cow.

[0071] Collection and transportation of cattle blood

[0072] Before collecting bovine blood, add 100 mg of sodium heparin to a 500 mL serum bottle to achieve a final concentration of 200 mg / L. During the collection process, slowly shake the serum bottle to ensure that the bovine blood and sodium heparin are evenly mixed. After collection, transport the bovine blood at 4°C to the serum substitute preparation laboratory.

[0073] Preparation of serum replacement

[0074] Place the collected bovine blood in a biosafety cabinet and aliquot it. First round of low-speed centrifugation: Centrifuge at 800g for 10 minutes at 4°C. Slowly remove the centrifuge tube from the centrifuge. This will separate into a supernatant and a precipitate. The precipitate consists of a white blood cell layer near the top and a red blood cell layer below. Collect the supernatant into a 250mL serum bottle, labeled A1, and store at 4°C. Second round of high-speed centrifugation: Centrifuge the precipitate from which the supernatant has been removed at 2100g for 15 minutes at 4°C. Carefully aspirate the supernatant into a 500mL serum bottle, labeled A2. Mix A1 and A2 evenly and label the mixture A3. Frozen A3 at -80°C.

[0075] A3 was removed and equilibrated at room temperature for 10 minutes. It was then placed in a 37°C constant-temperature water bath, with the water in the bath covering two-thirds of the bottle. The bottle was shaken at 80-100 rpm to thaw, and the temperature was observed every 10 minutes. When an ice-water mixture (0°C) formed in the bottle, the bottle was immediately removed, indicating that thawing was complete. A3 was again frozen in a -45°C ultra-low temperature freezer for at least 12 hours until it was completely frozen. This was recorded as one freeze-thaw cycle. This freeze-thaw cycle (i.e., thawing and freezing) was repeated four times.

[0076] After four freeze-thaw cycles, thaw A3 in a 37°C water bath. Finally, filter the serum through a 0.22 μm filter membrane to prepare a serum substitute. Dispense the serum into new serum bottles and freeze at -15°C or below for later use.

[0077] Example 4 Comparison of serum and serum replacement in culturing primary human mesenchymal stem cells

[0078] Comparison of serum and serum replacement in culturing primary human umbilical cord mesenchymal stem cells

[0079] Obtain intact human umbilical cord tissue, use large surgical scissors to cut off 1 cm at both ends of the umbilical cord, then rinse it several times to remove blood, use small scissors to cut the outer amniotic layer along the umbilical vein only, use tissue forceps to bluntly separate along the small opening, tear the amniotic layer completely, flatten it, and tear off the vein and artery.

[0080] Transfer the devascularized tissue to a 50 mL centrifuge tube containing 10 mL of digestive enzyme. Use large surgical scissors to chop the tissue into pieces of about 1 mm3. Seal the tube with sealing film and transfer it to a 37°C shaking incubator at 60-80 times / min for 2-3 hours of shaking and digestion.

[0081] The digestive enzymes used were prepared according to the following formula: 20 mg / mL collagenase IV (Sigma-Aldrich), 40 mg / mL Dispase II (Sigma-Aldrich), 500 mM CaCl2 (Sigma-Aldrich), 20 mg / mL hyaluronidase (Beijing Solaibao Technology Co., Ltd.), and 50 mM HEPES (buffer, BBI Life Science).

[0082] After the enzymatic hydrolysis is completed, the surface of the test tube is disinfected with 75% ethanol, and then transferred to a biosafety cabinet, 30 mL of balanced salt solution HBSS is added, the mixture is diluted and mixed, and filtered using a 100 μm cell strainer.

[0083] The obtained filtrate was divided into 15 mL centrifuge tubes, with each centrifuge tube divided into about 10 mL of filtrate, and centrifuged at room temperature for 6 minutes at 400 g. After centrifugation, the supernatant was slowly removed, and 1 mL of 10% fetal bovine blood (prepared in Example 3) + 1% penicillin / streptomycin DMEM / F12 culture medium (purchased from Shanghai Source Biotechnology Co., Ltd.) was added to resuspend the precipitated cells. After merging into one tube, the cells were centrifuged at 400 g for 6 minutes. The supernatant was discarded, and 1 mL of 10% fetal bovine blood (prepared in Example 3) + 1% penicillin / streptomycin DMEM / F12 culture medium (purchased from Shanghai Source Biotechnology Co., Ltd.) was resuspended to obtain primary mesenchymal stem cells. An equal amount of AO / PI reagent was added and mixed evenly, and the cells were counted using a Countstar fluorescence counter. For details on the use of the automatic cell counter, see "Standard Operating Procedure for the Use of Countstar Rigel S2 Automatic Cell Counter" WWSC-0024-CC. The cell harvest of primary umbilical cord mesenchymal stem cells was counted.

[0084] The above experiment was repeated using fetal bovine serum (purchased from Ecosine Biotechnology (Taicang) Co., Ltd.) instead of the fetal bovine serum substitute (prepared in Example 3), and primary umbilical cord mesenchymal stem cells were isolated and cultured. The cell yield was counted. The results are shown in Figure 1.

[0085] Comparison of serum and serum replacement in culturing primary human hair follicle mesenchymal stem cells

[0086] Primary human hair follicle mesenchymal stem cells were obtained as described in Example 2. These cells were isolated and cultured in DMEM / F12 medium containing 10% fetal bovine serum (purchased from Ecosine Biotechnology (Taicang) Co., Ltd.) and 10% fetal bovine serum substitute (prepared in Example 3), respectively. The cell yield was calculated. The results are shown in Figure 2.

[0087] Figures 1 and 2 show that whether it is human umbilical cord mesenchymal stem cells or human hair follicle mesenchymal stem cells, fetal bovine serum substitute used in the culture medium can enhance the proliferation ability of primary cells and increase the growth of primary cells.

[0088] Example 5 Comparison of Stem Cell Differentiation Ability in Serum and Serum Replacement Cultures

[0089] The prepared fetal bovine serum substitute (prepared in Example 3) and commercial fetal bovine serum (purchased from Ecosai Biotechnology (Taicang) Co., Ltd.) were used to culture and induce cell differentiation as described below.

[0090] Adipogenic differentiation and staining:

[0091] First, plate the hair follicle mesenchymal stem cells. Treat two wells of a 12-well plate with gelatin and let them dry for 15 minutes at room temperature or in a cell culture incubator. 5 Cells were placed in a 15 mL centrifuge tube and 10% fetal bovine serum substitute prepared in Example 3 or 10% commercial fetal bovine serum + human mesenchymal stem cell serum-free medium (purchased from TBD Biological Products Technology Co., Ltd.) was added to a total volume of 2.5 mL, i.e., a final concentration of 1.0×10 5 10 cells / mL, gently invert up and down 8 times to mix thoroughly. Immediately plate the mixed hair follicle mesenchymal stem cells into two wells of a coated 12-well plate, with 1 mL of cell suspension per well. Shake 5 times and observe the mixture under a microscope. Incubate in a 37°C incubator.

[0092] Next, proceed to adipogenic differentiation. When the plated hair follicle mesenchymal stem cells reach 90-100% confluency, remove the culture medium from the wells in a clean hood and add 1 mL of MesenCult Adipogenic Differentiation Medium (Human), purchased from STEMCELL Technologies. Discard the old culture medium and replace it with fresh differentiation medium every three days. Preheat the medium in a 37°C water bath for 15 minutes before use.

[0093] Finally, stain with Oil Red O. On the fourteenth day of adipogenic differentiation, aspirate the culture medium in each well and add 1 mL of PBS. Shake the wells three times, then aspirate the PBS. Add 0.5 mL of 4% paraformaldehyde fixative to each well and aspirate the wells three times to completely soak the bottom of the well. Let stand at room temperature for 15 minutes. Aspirate the fixative and add 1 mL of PBS. Shake the wells three times, then aspirate the PBS. Add 0.4 mL of freshly prepared Oil Red O staining solution to each well and aspirate the wells three times to completely soak the bottom of the well. Let stand at room temperature for 8 minutes. Add 1 mL of isopropanol and aspirate the wells. Add 1 mL of PBS and aspirate the wells three times to thoroughly soak the bottom of the well. Add 0.1-0.2 mL of PBS and observe the staining. Adipogenesis results are shown in Figure 3, and adipogenesis rate (%) results are shown in Table 2.

[0094] Table 2 Adipogenesis rate of stem cells cultured with serum substitutes and commercial serum (%)

[0095] As can be seen from Table 2 above, compared with commercial fetal bovine serum, fetal bovine serum substitutes used in culture medium can significantly enhance the adipogenic ability of hair follicle mesenchymal stem cells.

[0096] Chondrogenic differentiation and detection of its related gene expression:

[0097] First, differentiation induction culture was performed. Human hair follicle mesenchymal stem cells were resuspended in a serum-free medium containing 10% fetal bovine serum substitute prepared in Example 3 or 10% commercial fetal bovine serum + human mesenchymal stem cell (purchased from TBD Biological Products Technology Co., Ltd.) to adjust the cell concentration to 1×10 7cells / mL. In a clean bench, add the above cell suspension at a rate of 15 μL / drop to the inner surface of a 10 cm culture dish lid. Add 5 mL of PBS to the bottom of the culture dish to keep it moist. Carefully close the lid of the dish with the cell suspension and place it in a cell culture incubator for 24 hours. The cell suspension on the lid will aggregate into spheres. Use a Pasteur pipette to carefully transfer the microspheres to a low-adsorption 24-well plate containing 1 mL of chondrogenic differentiation induction medium (MesenCult ACF Chondrogenic Differentiation Basal Medium, purchased from STEMCELL Technologies). Replace 1-1.5 mL of new chondrogenic differentiation induction medium every 3 days. Collect the cell spheres in a 1.5 mL centrifuge tube on the 3rd day. Wash twice with 1 mL of PBS, aspirate the PBS, add 50 μL of Trizol lysis buffer (purchased from Nanjing Novozymes Biotechnology Co., Ltd.) to each tube, grind the cell microspheres with a high-speed tissue grinder for 15 seconds until the microspheres are broken into small fragments, then add 950 μL of lysis buffer to each tube, repeatedly pipette tip 5 times, vortex for 30 seconds, until the microspheres are completely lysed and no particles are visible to the naked eye.

[0098] Next, we examined the expression of genes involved in chondrogenic differentiation. We first extracted total RNA, reverse transcribed it into cDNA, and then analyzed gene expression using qPCR.

[0099] Add 100 μL of BCP (1-bromo-3-chloropropane) to the lysate of the cell microsphere sample, mix on a vortex for 15 seconds, let it stand on ice for 5 minutes, and centrifuge at 12,000 rpm at 4°C for 15 minutes. Carefully remove the EP tube and immediately gently pipette about 500 μL of the upper aqueous phase into a new 1.5 mL RNase-free EP tube. Add an equal volume of isopropanol, vortex to mix, and freeze at -80°C for more than 30 minutes. Centrifuge at 12,000 rpm at 4°C for 20 minutes, discard the supernatant, add 1 mL of pre-chilled 75% ethanol, and wash the precipitate by inverting. Centrifuge at 12,000 rpm at 4°C for 5 minutes, discard the supernatant, open the lid and dry the precipitate at room temperature, add 15-20 μL of DNase / RNase-free HO, let it stand on ice for 5 minutes, mix on a vortex and briefly centrifuge to completely dissolve the precipitate. Take 1 μL of the total RNA solution to determine the RNA concentration, record the test results, and take 1 μg of RNA for subsequent reverse transcription. The total RNA was reverse-transcribed into cDNA at 25°C for 10 minutes, 42°C for 30 minutes, and 85°C for 1 minute. Primers and the corresponding qPCR system (PerfectStart Green qPCR SuperMix) were prepared to detect the expression of genes related to chondrogenic differentiation ("Study on comprehensive evaluation strategy of chondrogenic differentiation ability of human mesenchymal stem cells in vitro", Zhang Kehua et al., Chinese Journal of New Drugs, 2017, 26(18), 2196-2203). The ratio of up-regulated genes to total genes related to chondrogenic differentiation in human hair follicle mesenchymal stem cells cultured in culture medium containing fetal bovine serum substitute or commercial fetal bovine serum was obtained, and the results are shown in Table 3 below.

[0100] Table 3 The proportion of up-regulated genes in the total genes related to chondrogenic differentiation (%)

[0101] Table 3 shows that, compared with commercial fetal bovine serum, the use of fetal bovine serum substitute in the culture medium can enhance the expression of genes related to chondrogenic differentiation, indicating enhanced chondrogenic differentiation.

[0102] Although the present invention has been described with reference to specific examples, it will be apparent to those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention. Therefore, the appended claims cover all such variations within the scope of the present invention.

Claims

1. A serum replacement, characterized in that The serum substitute contains platelet lysate and plasma, and the platelet lysate and plasma are derived from fetal bovine or newborn calf; preferably, the serum substitute consists of platelet lysate and plasma; preferably, the fetal bovine is a bovine embryo aged 5-8 months in a pregnant cow, and the newborn calf is a calf that is within 14 hours of birth and has not eaten.

2. The serum replacement according to claim 1, wherein The serum substitute is prepared from platelet plasma by platelet lysis.

3. The serum replacement according to claim 2, characterized in that The platelet-rich plasma is prepared by separating and removing blood cells other than platelets from whole blood of fetal bovine or newborn calf; optionally, it further has one or more of the following characteristics: The whole blood of the fetal bovine or newborn calf is anticoagulated; The separation is carried out by centrifugation, preferably low-temperature centrifugation; the centrifugation is preferably differential centrifugation; The platelet lysis was performed using a freeze-thaw method.

4. A method for preparing the serum substitute according to claim 1, characterized in that: The method comprises subjecting fetal bovine or newborn calf-derived platelet plasma to platelet lysis.

5. The method according to claim 4, wherein The method further comprises the following steps: a) separating and removing blood cells other than platelets from fetal bovine whole blood or newborn calf whole blood to obtain the platelet-rich plasma; preferably, the fetal bovine whole blood or newborn calf whole blood is anticoagulated; b) Optionally, after platelet lysis, sterilizing grade filtration is performed.

6. The method according to claim 5, wherein In step a), blood cells other than platelets are separated and removed by centrifugation, preferably at low temperature; preferably, the centrifugation speed is 400g to 2100g, for example, 400g to 1000g, 1800g to 2100g, and the centrifugation time is 10-30 minutes, for example, 10-25 minutes, 15-30 minutes; preferably, the low temperature is below 10°C, or below 5°C.

7. The method according to claim 6, wherein The centrifugation method is a differential centrifugation method, comprising at least one low-speed centrifugation to obtain a platelet-plasma supernatant layer and a sediment layer enriched with blood cells other than platelets, and at least one high-speed centrifugation to secondary separate the plasma and blood cells that were not completely separated by the low-speed centrifugation, and comprising combining the supernatant collected before platelet lysis and / or combining the supernatant obtained by the high-speed centrifugation after platelet lysis; Preferably, the differential centrifugation comprises at least one low-speed centrifugation with a centrifugal speed of 400 g to 1000 g and a time of 10 to 25 minutes; and At least one high-speed centrifugation is performed at a speed of 1800g to 2100g for 15-30 minutes.

8. The method according to claim 4, wherein The platelet lysis is performed by a freeze-thaw method; preferably, the freeze-thaw method has one or more of the following characteristics: The number of freeze-thaw cycles was 3-7 times; Freeze for at least 8 hours; The freezing temperature is not higher than -20°C, preferably, the freezing temperature is -80°C; The temperature of the melt is 0°C.

9. Use of the serum substitute according to any one of claims 1 to 3 in culturing stem cells, wherein the stem cells do not include cells isolated or obtained from a human embryo that is more than 14 days post-fertilization or has undergone in vivo development; preferably, the stem cells are mesenchymal stem cells; more preferably, the stem cells are selected from human hair follicle mesenchymal stem cells, human umbilical cord mesenchymal stem cells, human adipose mesenchymal stem cells, and human endometrial mesenchymal stem cells.

10. Use of the serum substitute according to any one of claims 1 to 3 in inducing stem cell differentiation, wherein the stem cells do not include cells isolated or obtained from a human embryo that is more than 14 days post-fertilization or has undergone in vivo development; preferably, the stem cells are mesenchymal stem cells; more preferably, the stem cells are selected from human hair follicle mesenchymal stem cells, human umbilical cord mesenchymal stem cells, and human endometrial mesenchymal stem cells; preferably, the differentiation can be, for example, adipogenic differentiation or chondrogenic differentiation.